首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 62 毫秒
1.
60Coγ射线照射对人血小板功能的影响   总被引:1,自引:0,他引:1       下载免费PDF全文
以不同剂量的60Coγ射线照射富含血小板血浆后,检测其代谢及释放产物的变化60Coγ射线照射剂量达5Gy时,血小板表面活化标记蛋白GMP-140分子的表达显着增多,且随剂量的增加而增高,血浆内血小板TxB2的产生及释放当剂量为2.5Gy时就呈显着升高,γ射线剂量大于5Gy时,血浆内vWF的浓度显着升高;结果提示;60Coγ射线照射剂量达5 Gy后,可激活体外的血小板,导致后者代谢旺盛。内容物释放增多。  相似文献   

2.
部分照射离体血对淋巴细胞染色体畸变形成的影响   总被引:1,自引:1,他引:0       下载免费PDF全文
目的 分析60Coγ射线部分照射离体血对人外周血淋巴细胞染色体畸变形成的影响。方法 用2Gy60Coγ射线37℃照射人外周血后以不同比例混合后进行培养、制片和分析染色体畸变。结果 染色体畸变随照射血比例的增加而增加,与单纯照射组相比,混合照射血的染色体畸变率高。1:1比例混合估算出的剂量为1.27Gy,大于1Gy;0.5:1比例混合估算出的剂量为0.93Gy,大于0.5Gy;而在1:0组,照射剂量与估算剂量基本一致。结论 染色体畸变可以作为估算非均匀照射的生物学指标之一。  相似文献   

3.
目的 探讨日射量的估算方法及太阳光辐射对牙釉质电子自旋共振(ESR)剂量学的影响。方法 用机械方法获得11个牙釉质样品。用照度计测量太阳光的照度,通过比较日本气象厅在广岛市测得的瞬时日射量和相同时刻所测得的照度,计算出转换系数,然后估算出照射在牙釉质样品的累积日射量。用6060Co γ射线和太阳光分别照射牙釉质样品,使用ESR波谱仪测量不同辐射后牙釉质样品的ESR信号。结果 照度与瞬时日射量的转换系数为(8.67±0.22) W·m-2klx。照射在牙釉质样品上的累积日射量为(580±16) MJm2。太阳光辐射也引起γ射线照射产生的剂量学信号,而且随累积日射量而线性增强,太阳光辐射还产生一个紧邻本底的信号,当累积日射量大于某一值时,该信号趋于饱和状态。结论 用剂量学信号对所受辐射剂量进行评价,本研究中每MJm2的太阳光辐射的影响相当于(7.7±1.4) mGy的γ射线辐射。紧邻本底的ESR信号可作为太阳光辐射的标志峰,有助于判断所收集的样品是否受到太阳光辐射,从而提高小剂量重建的准确度。  相似文献   

4.
目的 探讨不同剂量60Coγ射线对EJ细胞DNA损伤的情况,不同剂量60Coγ 射线照射EJ细胞后诱导磷酸化组蛋白H2AX焦点形成,以及与γH2AX表达量的关系。方法 单细胞凝胶电泳检测DNA链断裂损伤情况。免疫荧光法检测不同剂量γ 射线照射后立即、以及2 Gy γ 射线照射后不同时间的EJ细胞中γH2AX焦点的数量。流式细胞分析法检测不同剂量γ 射线照射后EJ细胞中γH2AX 蛋白表达量的变化。结果 单细胞凝胶电泳结果显示,γ射线照射后DNA损伤情况明显加重,随照射剂量的增加,细胞尾矩不断加大,0 Gy组尾矩为0.24,4 Gy照射组尾矩为5.26;免疫荧光结果显示,随着照射剂量的增加,γH2AX焦点数目及大小均明显增加,照射的剂量范围从0.1~4 Gy均可检测,且照射剂量和焦点形成数目之间存在剂量-效应关系,0.1 Gy照射组每个细胞中的焦点数平均达12.37个,4 Gy照射组每个细胞中的焦点数平均达46个;2 Gy γ 射线照射后24 h仍可检测到γH2AX焦点,随时间延长焦点数目减少、强度减弱,具有时间依赖性。流式细胞检测结果表明,γ 射线照射后γH2AX 蛋白表达量明显增加,呈现明显量效关系,0.1和4 Gy照射组γH2AX阳性细胞表达率分别为7.4%和29.2%。结论 免疫荧光法检测照射后γH2AX焦点数目比其他实验方法更能敏感、直观的反映DNA损伤及修复情况,有望成为检测辐射损伤的理想生物指标。  相似文献   

5.
目的 研究嚼烟习俗对牙釉质电子自旋共振(ESR)剂量学的影响。方法 用机械方法获得20个孟买地区的舌侧牙釉质样品与10个混合均匀的日本人舌侧牙釉质样品。用60Co γ射线分别照射部分牙釉质样品,使用ESR波谱仪测量辐射前和不同辐射剂量后牙釉质样品的ESR信号。结果 9个孟买牙釉质样品,其ESR的本底信号强度明显高于日本人的平均水平,为日本人水平的1.5~3.3倍。ESR本底信号强度较高的样品,γ射线照射后,剂量学信号的辐射响应略低,说明高本底可能降低了辐射剂量的灵敏度。6个样品辐射响应的平均值为(0.42±0.03)mGy,与日本牙釉质混合样品很相近。结论 嚼烟地区的部分牙釉质的ESR本底水平明显高于一般平均水平,可能是嚼烟中大量的烟碱与牙釉质相互作用的结果。进一步研究特殊生活习俗对牙釉质ESR剂量学的影响,有助于提高不同地区剂量重建的精度,为正确地评价辐射事故剂量提供科学依据。  相似文献   

6.
60Coγ射线照射对血管内皮细胞纤溶功能的影响   总被引:1,自引:0,他引:1       下载免费PDF全文
人脐静脉内皮细脆在体外用60Coγ射线照射.剂量为0~50Gy。照射后早期内皮细胞培养液巾t-PA抗原和活性都迅速增高, 其增加幅度与照射剂量高低相一致, PAI活性则降低, 照射6天后t-PA抗原和活性都随着照射剂量的增加而降低, PAI活性增高。  相似文献   

7.
目的 建立检测γ射线照射剂量的新方法,探讨应用金纳米颗粒复合材料(ssDNA-AuNPs)比色检测γ射线照射剂量的可行性。方法 将寡核苷酸分子(ssDNA)修饰到金纳米颗粒(AuNPs)表面,制备出复合材料ssDNA-AuNPs。用60Co γ射线对其进行照射,剂量分别为0、5、10、20和30 Gy,而后观察溶液颜色变化并测量紫外-可见吸收光谱,建立吸收光谱中625 nm处与521 nm处吸光度的比值(A625/A521)与照射剂量线性关系。结果 随着60Co γ射线照射剂量的不断增加,ssDNA-AuNPs溶液的颜色由酒红色逐渐变为蓝紫色。在0~30 Gy剂量范围内,吸收光谱中A625/A521的比值对其拟合线性方程为A625/A521=0.020 6+0.303 6ER2=0.991 5)。结论 本实验合成的ssDNA-AuNPs能够比色检测γ射线照射剂量,建立了一种比色检测γ射线照射剂量的新方法。  相似文献   

8.
目的 探讨超大剂量γ射线离体照射后人外周血淋巴细胞染色体畸变的量效关系,建立双+环(dic+r)大剂量-效应曲线。方法 外周静脉血样采自3名健康男性,经 60Co γ线(0~50 Gy,剂量率2.35Gy/min)照射。采用即刻加秋水仙素的微量全血法,分别培养52、72及96h。计数有丝分裂指数(MI)、双着丝粒体(dic)和环(r)畸变数,拟合dic+r剂量-效应曲线,对2例受大剂量照射的事故患者进行剂量估算。结果 MI随照射剂量的增加而逐渐减少。每细胞dic+r频率随照射剂量增加而增加直到23Gy(5Gy之后增加幅度较前变小),>23Gy后趋于饱和。对所获数据进行回归分析,拟合dic+r大剂量-效应曲线(5~23Gy):每细胞dic+r频率y=-1.608(±0.300)+0.830 (±0.051)D-0.013(±0.002) D2 (R2=0.998)。用拟合曲线对2例受照患者剂量的估算结果与用物理方法和电子自旋共振(ESR)法估算的剂量及临床表现基本一致。结论 本研究建立的dic+r大剂量-效应曲线, 可估计的上限剂量达23Gy,有可能提高常规染色体畸变分析用作生物剂量计的实用价值。  相似文献   

9.
目的 应用绿色荧光蛋白(GFP)标记的基因组不稳定性报告系统,检测60Coγ射线诱导B16细胞区域性基因组不稳定性改变。方法 实验分为3组:未转染组、转染组及转染对照组。应用脂质体转染法,将GFP标记目的质粒及对照质粒分别转入B16细胞,经G418筛选,有限稀释法培养形成单克隆生长。给予0、2和4 Gy 60Coγ 射线照射,共聚焦荧光显微镜记录GFP表达细胞数,计算GFP表达率。结果 建立了含有GFP标记的区域性基因组不稳定性报告系统的GFP-B16细胞株。60Coγ射线照射后,2和4 Gy组均可见GFP-B16细胞表达GFP,并与照射剂量、照射后时间密切相关。GFP表达率随照射剂量(F=36.55、36.76,P<0.05)和照射后时间的增加而增高(t=-3.27、-3.16、-4.26、-6.11、-7.17, P<0.05)。照射后第3天,GFP表达率增高幅度最明显(2.46±0.24),第5天达到高峰(3.82±0.35),增高幅度趋于稳定。0 Gy组在照射后2周,自发绿色荧光蛋白表达率为1/60万。结论 GFP标记的基因组不稳定性报告系统可检测到60Coγ射线诱导的B16细胞区域性基因组不稳定性改变。  相似文献   

10.
目的 探讨不同剂量率60Co γ射线照射对辐射诱导的基因表达水平改变的影响。方法 60Co γ射线照射3例正常人离体外周血,剂量率分别为0.2、1.0和2.0 Gy/min,照射剂量为0、1、2、4和6 Gy,照射后24 h收集细胞,实时荧光定量(PCR)法对11个基因(CDKN1A、MDM2、PCNA、FDXR、GADD45A、PHPT1、ASTN2、TNFSF4、POLH、GDF-15和PPM1D) mRNA表达水平进行相对定量检测;逐步回归法构建不同剂量率基因组合表达模型。结果 不同剂量率0.2、1和2 Gy/min 60Co γ射线照射后,辐射诱导的11个基因的相对表达量随照射剂量增加而升高,具有显著的剂量依赖性(R2=0.744~0.998,P< 0.05);0.2 Gy/min 60Co γ射线照射2 Gy后,CDKN1A、FDXR、PHPT1和TNFSF4基因的表达量明显高于1和2 Gy/min剂量率组,差异具有统计学意义(t=3.73、5.73、2.44、2.77、3.53、2.68、2.43、2.05,P< 0.05);2 Gy/min 60Co γ射线照射6 Gy后,PPM1D基因表达量明显高于其他两个剂量率组(t=3.82、2.54,P< 0.05);不同剂量率基因组合表达模型由2~3个基因组成,回归方程的R2值为0.951~0.976(P< 0.05)。结论 在0.2~2 Gy/min剂量率范围内,不同剂量率60Co γ射线照射可能会影响辐射诱导人外周血基因表达水平的改变。  相似文献   

11.
The Knee injury and Osteoarthritis Outcome Score (KOOS) is a self-administered instrument measuring outcome after knee injury at impairment, disability, and handicap level in five subscales. Reliability, validity, and responsiveness of a Swedish version was assessed in 142 patients who underwent arthroscopy because of injury to the menisci, anterior cruciate ligament, or cartilage of the knee. The clinimetric properties were found to be good and comparable to the American version of the KOOS. Comparison to the Short Form-36 and the Lysholm knee scoring scale revealed expected correlations and construct validity. Item by item, symptoms and functional limitations were compared between diagnostic groups. High responsiveness was found three months after arthroscopic partial meniscectomy for all subscales but Activities of Daily Living.  相似文献   

12.
13.
14.
Objective To investigate endovascular treatment of traumatic direct carotid-cavernous fistulas (CCF) and their complications such as pseudoaneurysms. Methods: Over a five-year period, 22 patients with traumatic direct CCFs were treated endovascularly in our institution. Thirteen patients were treated once with the result of CCF occluded, 8 twice and 1 three times. Treatment modalities included balloon occlusion of the CCF, sacrifice of the ipsilateral internal carotid artery with detachable balloon, coll embolization of the cavernous sinus and secondary pseudoaneurysms, and covered-stem management of the pseudoaneurysms. Results All the direct CCFs were successfully managed endovascularly. Four patients developed a pseudoaneurysm after the occlusion of the CCF with an incidence of pseudoaneurysm formation of 18.2% (4/22). A total number of 8 patients experienced permanent occlusion of the ICA with a rate of ICA occlusion reaching 36.4% (8/22). Followed up through telephone consultation from 6 months to 5 years, all did well with no recurrence of CCF symptoms and signs. Conclusion Traumatic direct CCFs can be successfully managed with endovascular means. The pseudoaneurysms secondary to the occlusion of the CCFs can be occluded with stent-assisted coiling and implantation of covered stents.  相似文献   

15.
Acute limping may be the result of multiple pathologies in children. The differential diagnosis varies based on the age of the child. Irrespective of age, the initial imaging work-up includes AP and frog leg radiographs of the pelvis and ultrasound; MRI may sometimes be helpful. In children less than 3 years, infections and trauma are most frequent. MRI is the imaging modality of choice when osteomyelitis is clinically suspected. Between the ages of 3 and 10 years, transient synovitis of the hip and Legg-Calvé-Perthes disease are main considerations but infection, inflammation and focal bony lesions are also considered. In children over 10 years, slipped capital femoral epiphysis also is considered.  相似文献   

16.
Introduction Ankle sprains are the most common musculo-skeletal injury that occurs in athletes,particularly in sports that require jumping and landing on one foot such as soccer,and basketball(1-4).These injuries often result in significant time loss from participation,long-term disability,and have a major impact on health care costs and resources(5-8).  相似文献   

17.
18.
KEY POINTS ·High-intensity interval training(HIT)is characterized by repeated sessions of relatively brief,intermittent exercise.often performed with an“a11 out”effort or at an intensity close to that which elicits peak oxygen uptake(i.e.,≥90%of VO2 peak).  相似文献   

19.
20.
In response to the ENFSI and EDNAP groups’ call for new STR multiplexes for Europe, Promega® developed a suite of four new DNA profiling kits. This paper describes the developmental validation study performed on the PowerPlex® ESI 16 (European Standard Investigator 16) and the PowerPlex® ESI 17 Systems. The PowerPlex® ESI 16 System combines the 11 loci compatible with the UK National DNA Database®, contained within the AmpFlSTR® SGM Plus® PCR Amplification Kit, with five additional loci: D2S441, D10S1248, D22S1045, D1S1656 and D12S391. The multiplex was designed to reduce the amplicon size of the loci found in the AmpFlSTR® SGM Plus® kit. This design facilitates increased robustness and amplification success for the loci used in the national DNA databases created in many countries, when analyzing degraded DNA samples. The PowerPlex® ESI 17 System amplifies the same loci as the PowerPlex® ESI 16 System, but with the addition of a primer pair for the SE33 locus. Tests were designed to address the developmental validation guidelines issued by the Scientific Working Group on DNA Analysis Methods (SWGDAM), and those of the DNA Advisory Board (DAB). Samples processed include DNA mixtures, PCR reactions spiked with inhibitors, a sensitivity series, and 306 United Kingdom donor samples to determine concordance with data generated with the AmpFlSTR® SGM Plus® kit. Allele frequencies from 242 white Caucasian samples collected in the United Kingdom are also presented. The PowerPlex® ESI 16 and ESI 17 Systems are robust and sensitive tools, suitable for the analysis of forensic DNA samples. Full profiles were routinely observed with 62.5 pg of a fully heterozygous single source DNA template. This high level of sensitivity was found to impact on mixture analyses, where 54–86% of unique minor contributor alleles were routinely observed in a 1:19 mixture ratio. Improved sensitivity combined with the robustness afforded by smaller amplicons has substantially improved the quantity of data obtained from degraded samples, and the improved chemistry confers exceptional tolerance to high levels of laboratory prepared inhibitors.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号